At a glance
ClinicalIndex Comparison RecordN/ACompleted· 45 enrolled
Drug / intervention
EndoBarrier Gastrointestinal Linerdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner
In Brief
A clinical study evaluating EndoBarrier Gastrointestinal Liner for Type 2 Diabetes and Obesity. Completed, enrolled 45 participants across 3 sites.
Detailed Summary
The purpose of this study is to evaluate EndoBarrier Gastrointestinal Liner in the post marketing environment in subjects who are obese and have Type 2 Diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Obesity
CountriesUnited Kingdom
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartOct 2010
Primary CompletionJan 2013
Study CompletionJul 2013
TodayJul 2026
First PostedMay 3, 2010
Enrollment StartOct 1, 2010
Primary CompletionJan 1, 2013
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.2 years ago
Interventions
EndoBarrier Gastrointestinal Linerdevice
EndoBarrier Gastrointestinal Liner is intended to remain in vitro for 12 months.